Sonnet BioTherapeutics, Inc. (NASDAQ:SONN)

BRIEF

published on 05/22/2024 at 13:05, 6 months 30 days ago

Sonnet BioTherapeutics Announces Review of Strategic Alternatives

Strategic Review Sonnet BioTherapeutics Chardan Capital Markets Stockholder Value Immunotherapeutic Drugs
PRESS RELEASE

published on 05/22/2024 at 13:00, 6 months 30 days ago

Sonnet BioTherapeutics Announces Review of Strategic Alternatives
Sonnet BioTherapeutics Holdings, Inc. initiates review of strategic alternatives to maximize stockholder value with financial advisor Chardan Capital Markets. Evaluation may lead to various strategic transactions but no definitive decisions made yet

Strategic Alternatives FHAB Technology Sonnet BioTherapeutics Holdings Inc. Chardan Capital Markets Immunotherapeutic Drugs
BRIEF

published on 05/20/2024 at 15:20, 7 months 1 day ago

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010

Clinical Trials Cancer Treatment Immunotherapy Sonnet BioTherapeutics SON-1010
PRESS RELEASE

published on 05/20/2024 at 15:15, 7 months 1 day ago

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Sonnet BioTherapeutics reports positive safety and efficacy data from Phase 1 clinical trials of SON-1010, a novel immunotherapeutic drug for solid tumors, demonstrating extended half-life and clinical benefit in patients

Solid Tumors Sonnet BioTherapeutics SON-1010 Immunotherapeutic Drug Phase 1 Clinical Trials
BRIEF

published on 05/14/2024 at 22:20, 7 months 6 days ago

Sonnet BioTherapeutics Announces Fiscal Year 2024 Q2 Results and Business Updates

Financial Results Clinical Trials Oncology Biopharmaceuticals Sonnet BioTherapeutics
PRESS RELEASE

published on 05/14/2024 at 22:15, 7 months 6 days ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
Sonnet BioTherapeutics announces financial results and corporate updates including Phase 1 data on SON-1010 safety, net proceeds from tax program, and clinical trial progress on SON-080 for CIPN

Financial Results Biopharmaceutical Clinical Trial Sonnet BioTherapeutics Safety Data
BRIEF

published on 05/06/2024 at 13:05, 7 months 15 days ago

Sonnet BioTherapeutics to Present at EF Hutton Annual Global Conference

Biopharmaceuticals Sonnet BioTherapeutics Investor Meetings EF Hutton Conference Innovative Drugs
PRESS RELEASE

published on 05/06/2024 at 13:00, 7 months 15 days ago

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
Sonnet BioTherapeutics Holdings, Inc. to participate in EF Hutton Global Conference on May 15, 2024, presenting innovative biologic drugs. Learn about their oncology-focused technology

Sonnet BioTherapeutics Holdings Inc. EF Hutton Annual Global Conference Innovative Biologic Drugs Oncology-focused Technology Investment Bank
BRIEF

published on 03/19/2024 at 12:35, 9 months 2 days ago

Sonnet BioTherapeutics to Showcase SON-080 Research at AACR 2024

Biopharmaceuticals Sonnet BioTherapeutics SON-080 CIPN AACR 2024
PRESS RELEASE

published on 03/19/2024 at 12:30, 9 months 2 days ago

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
Sonnet BioTherapeutics to present preclinical data on SON-080 for neuropathies at AACR Annual Meeting 2024. The study focuses on safety and clinical plans using recombinant human Interleukin-6

Biopharmaceutical Sonnet BioTherapeutics SON-080 AACR Annual Meeting Interleukin-6

Published on 12/21/2024 at 01:30, 17 hours 26 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 17 hours 26 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 18 hours 51 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 18 hours 56 minutes ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 19 hours 26 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

Published on 12/21/2024 at 00:51, 18 hours 4 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 10 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 23 hours 45 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 23 hours 59 minutes ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 1 day ago

ARYZTA AG Announces New Board Technology Committee

View all EQS

Published on 12/21/2024 at 12:17, 6 hours 38 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 1 hour ago

Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 4 hours ago

Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 2 days ago

Share capital decrease by way of treasury shares cancellation

View all LES ECHOS COMFI WIRE

News